Our goal is to target global markets with innovative PCR products, custom oligonucleotide synthesis, monoclonal antibody development, and comprehensive drug discovery services. Diversified biotech, that is DIANA Biotechnologies!
About
DIANA Biotechnologies was established in 2018 as a biotech company at the Institute of Organic Chemistry and Biochemistry (IOCB), Academy of Sciences in Prague, with the goal of building on its global reputation and strong track record in drug discovery. We have raised substantial venture capital funding and have been awarded exclusive global rights to the DIANA technology.
Our team combines a unique set of expertise in medical and organic chemistry, biochemistry, and pharmacology, enabling us to harness the power of DIANA technology in clinical diagnostics, academic research, and the development of monoclonal antibodies and drug discovery services.
Private investment
Founded in 2018 based on DIANA technology and supported by 3.5 million EUR in private investment.
Million PCR tests delivered
We became the largest producer of COVID-19 tests in Czechia.
Segments
We provide innovative solutions for diagnostic and academic labs, develop monoclonal antibodies, and offer drug discovery services.
INTERESTED IN COLLABORATION?
CFO | COO
Martin Dienstbier
Contact us
